TROPION-Lung01 Study Design and Baseline demographics

Trastuzumab deruxtecan (T-DXd) for pretreated patients with HER2-expressing solid tumors: primary analysis from the DESTINY-Pan Tumor02 (DP-02) study Funda Meric-Bernstam, MD; a Vicky Makker; Ana Oaknin; Do-Youn Oh; Susana Banerjee; Antonio González-Martín; Kyung Hae Jung; Iwona Ługowska; Luis Manso; Aránzazu Manzano; Bohuslav Melichar; Salvatore Siena; Daniil Stroyakovskiy; Anitra Fielding; Yan Ma; Soham Puvvada; Jung-Yun Lee On behalf of the DESTINY-PanTumor02 investigators aUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA October 23, 2023 | 16:40-16:45 CEST Daiichi-Sankyo 44

View entire presentation